Investigating the Association Between Semaglutide Use and Mood Disorders in Polyendocrine Metabolic Ovarian Syndrome: A Retrospective Cohort Study
- Design
- Retrospective cohort
- Drugs
- Semaglutide
- Assessment
- Facts extracted automatically · reviewed by Carrie Schluter, Nov 5, 2026 · added Sep 20, 2026
This study was added automatically, and its details were extracted by machine rather than read off the paper by a person. Carrie Schluter has reviewed the record, but that review did not re-extract those details, so the collection still publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.
01Source
The source, as retrieved
Abstract
[OBJECTIVE] This retrospective cohort study aims to evaluate whether semaglutide use in patients with polyendocrine metabolic ovarian syndrome (PMOS) is associated with an increased risk of mood disorders compared to patients treated with metformin by utilizing a large, propensity-matched dataset from TriNetX. [METHODOLOGY] The TriNetX platform was used to conduct a retrospective cohort study with International Classification of Diseases, 10th Revision (ICD-10) codes to generate inclusion and exclusion criteria. After propensity matching, each cohort consisted of 20,535 patients, for a total sample size of 41,070. Cohort 1 (patients with PMOS and on metformin) and Cohort 2 (patients with PMOS and on semaglutide) were evaluated for outcomes of new-onset major depressive disorder, generalized anxiety disorder, insomnia, and suicidal ideation that emerged after the start of the medication of interest. [RESULTS] There was no statistically significant difference in generalized anxiety disorder and suicidal ideation associated with semaglutide use as compared to metformin in women with PMOS. However, there was a minor statistically significant difference in the rates of insomnia and major depressive disorder. [CONCLUSIONS] These results suggest that psychiatric considerations alone should not preclude the use of semaglutide in PMOS management. Ongoing mental health screening and follow-up remain essential for all patients with PMOS, regardless of treatment choice.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 20, 2026 | 42741750 first ingestion |
| pubmed | Sep 20, 2026 | 42741750 duplicate matched on doi |
| pubmed | Sep 27, 2026 | 42741750 duplicate matched on doi |
| pubmed | Sep 27, 2026 | 42741750 duplicate matched on doi |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |